… a combination of nirmatrelvir and ritonavir (NMV-r) for treating COVID-19 in patients with
diabetes … the TriNetX research network to identify adult diabetic patients with COVID-19 between …

… diabetes mellitus, exacerbation of pre-existing diabetes … HIV-1 infected patients receiving
lopinavir/ritonavir therapy, but a … this drug in those with diabetes mellitus or glucose intolerance. …

… patients with laboratory-confirmed SARS-CoV-2 infection with any one of the following criteria
will be eligible to receive lopinavir/ritonavir for … -age> 60 yr, diabetes mellitus, renal failure, …

… patients receiving atazanavir/ritonavir and 338 (76%) of 443 patients receiving lopinavir/ritonavir …
atazanavir/ritonavir group vs 219 cells per μL in the lopinavir/ritonavir group). 25 (6%) …

… -diabetic individuals (… -diabetic individuals and patients with type 2 diabetes [24] . Finally, a
decrease of similar magnitude in glucose disposal (∼30%) was found in HIV-positive patients …

… after a switch from a ritonavir-boosted PI (PI/r) to an integrase strand transfer inhibitor (INSTI)—raltegravir
or dolutegravir—in non-diabetic HIV-infected patients on stable cART. Insulin, …

… trial of lopinavir/ritonavir versus indinavir, it is of note that on lopinavir/ritonavir one patient
developed impaired glucose tolerance, whereas on indinavir, one developed diabetes and …

… The study aimed to investigate whether lopinavir/ritonavir (LPV/r) in combination with
other pneumonia-associated adjuvant drugs has a better therapeutic effect on COVID-19. …

… Objective: Evaluate efficacy and tolerability of lopinavir/ritonavir (LPV/r) plus stavudine
and lamivudine long term in antiretroviral-naïve patients. Design: Open-label follow-up of …

… was noted in the lopinavir/ritonavir simplification strategy. This study has provided important
information for future studies using treatment simplified to lopinavir/ritonavir monotherapy. …